These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 34322877)

  • 21. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma.
    Baba Y; Nomoto D; Okadome K; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Baba H
    Cancer Sci; 2020 Sep; 111(9):3132-3141. PubMed ID: 32579769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy.
    Han C; Zhang A; Liu Z; Moore C; Fu YX
    Oncogene; 2021 Feb; 40(5):885-898. PubMed ID: 33288883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
    Ayala-Mar S; Donoso-Quezada J; González-Valdez J
    J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
    Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
    Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gut Microbiota, the Immune System, and Cytotoxic T Lymphocytes.
    Cosola C; Rocchetti MT; Gesualdo L
    Methods Mol Biol; 2021; 2325():229-241. PubMed ID: 34053062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary.
    Sue-A-Quan R; Patel PG; Shakfa N; Nyi MN; Afriyie-Asante A; Kang EY; Köbel M; Koti M
    Gynecol Oncol; 2021 Aug; 162(2):421-430. PubMed ID: 34088514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes.
    Wang M; Zhang L; Chang W; Zhang Y
    Front Immunol; 2022; 13():1096551. PubMed ID: 36726985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma.
    Mima K; Sukawa Y; Nishihara R; Qian ZR; Yamauchi M; Inamura K; Kim SA; Masuda A; Nowak JA; Nosho K; Kostic AD; Giannakis M; Watanabe H; Bullman S; Milner DA; Harris CC; Giovannucci E; Garraway LA; Freeman GJ; Dranoff G; Chan AT; Garrett WS; Huttenhower C; Fuchs CS; Ogino S
    JAMA Oncol; 2015 Aug; 1(5):653-61. PubMed ID: 26181352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.
    Dammeijer F; van Gulijk M; Mulder EE; Lukkes M; Klaase L; van den Bosch T; van Nimwegen M; Lau SP; Latupeirissa K; Schetters S; van Kooyk Y; Boon L; Moyaart A; Mueller YM; Katsikis PD; Eggermont AM; Vroman H; Stadhouders R; Hendriks RW; Thüsen JV; Grünhagen DJ; Verhoef C; van Hall T; Aerts JG
    Cancer Cell; 2020 Nov; 38(5):685-700.e8. PubMed ID: 33007259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of the microbiota in response to and recovery from cancer therapy.
    Blake SJ; Wolf Y; Boursi B; Lynn DJ
    Nat Rev Immunol; 2024 May; 24(5):308-325. PubMed ID: 37932511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Biomarkers for Melanoma Immunotherapy.
    Twitty CG; Huppert LA; Daud AI
    Curr Oncol Rep; 2020 Feb; 22(3):25. PubMed ID: 32048065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
    Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.
    Philippou Y; Sjoberg HT; Murphy E; Alyacoubi S; Jones KI; Gordon-Weeks AN; Phyu S; Parkes EE; Gillies McKenna W; Lamb AD; Gileadi U; Cerundolo V; Scheiblin DA; Lockett SJ; Wink DA; Mills IG; Hamdy FC; Muschel RJ; Bryant RJ
    Br J Cancer; 2020 Sep; 123(7):1089-1100. PubMed ID: 32641865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors.
    Huang T; Li F; Cheng X; Wang J; Zhang W; Zhang B; Tang Y; Li Q; Zhou C; Tu S
    Front Immunol; 2021; 12():619209. PubMed ID: 33790893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The gut microbiota influences anticancer immunosurveillance and general health.
    Routy B; Gopalakrishnan V; Daillère R; Zitvogel L; Wargo JA; Kroemer G
    Nat Rev Clin Oncol; 2018 Jun; 15(6):382-396. PubMed ID: 29636538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.
    Zhang M; Bzura A; Baitei EY; Zhou Z; Spicer JB; Poile C; Rogel J; Branson A; King A; Barber S; Kamata T; Dzialo J; Harber J; Greystoke A; Nusrat N; Faulkner D; Sun Q; Nolan L; Hahne JC; Scotland M; Walter H; Darlison L; Morgan B; Bajaj A; Brookes C; Hollox EJ; Lubawska D; Jama M; Griffiths G; Nakas A; Kutywayo K; Luo JL; Klampatsa A; Cooper A; Halder K; Wells-Jordan P; Zhou H; Dudbridge F; Thomas A; Richards CJ; Pritchard C; Yang H; Barer M; Fennell DA
    Nat Commun; 2024 Aug; 15(1):7187. PubMed ID: 39168966
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Yin H; Miao Z; Wang L; Su B; Liu C; Jin Y; Wu B; Han H; Yuan X
    Aging (Albany NY); 2022 Feb; 14(4):1941-1958. PubMed ID: 35212644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Frontiers about the Role of Human Microbiota in Immunotherapy: The Immune Checkpoint Inhibitors and CAR T-Cell Therapy Era.
    Innao V; Allegra AG; Musolino C; Allegra A
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fusobacterium nucleatum carcinogenesis and drug delivery interventions.
    Chen Z; Huang L
    Adv Drug Deliv Rev; 2024 Jun; 209():115319. PubMed ID: 38643839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.